CONCLUSIONS
To date, IPLEX has been generally well tolera
ted and there have been no safety concerns
associated with IPLEX. Most of the patie
nts enrolled into the Program are at an
advanced stage of disease and a number of
patients have died while on IPLEX, but these
have been attributed by their physicians to dis
ease progression. It is
difficult to interpret
the changes of ALSFRS-R scores observe
d in the remaining
population because the
Program does not have a
concurrent control group.

(Reuters) - London-listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the healthcare sector, sources familiar with the matter told Reuters.

Much of the dealmaking has been fueled by U.S. companies seeking lower tax rates abroad. With its tax base in Ireland - where effective corporate tax rates are among the lowest in the world - and a mid-sized market value of around $35 billion, Shire could be a prime target, analysts and bankers believe.

Production of IPLEX will NOT be an issue (see underneath's update on ROP)

Periodic Report Summary 1 • PREVENTROP (New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP))
Project Context and Objectives:
Retinopathy of prematurity (ROP) is a major cause of blindness in children in the developed and developing world, despite current treatment of late-stage ROP. As developing countries provide more neonatal intensive care, the incidence of ROP is increasing as more preterm children are saved. Approximately 40% of perinatal blindness can be attributed to ROP. The treatment of ROP, ablation of the avascular retina with laser photocoagulation or cryotherapy to cause involution of pathological vessels, has remained fundamentally unchanged for almost 50 years. These treatments are destructive and destroy the peripheral (non-vascularised) parts of the retina and may lead to a partial loss of peripheral or side vision.
PREVENTROP consortium consists of ten partners from five EU Member States (SE, DE, UK, NL and IT), Norway and USA. The overall objective of the PREVENTROP project is to develop a novel preventative intervention for the blinding disease ROP and other complications of prematurity. This work is based on the concept that replacement of critical factor(s), normally provided in utero and reduced due to the disruption of the maternal/fetal interaction, to the infant born prematurely will help prevent the complications of premature birth.
It has been shown experimentally and clinically that low levels of the growth factor Insulin-like growth factor 1 (IGF-I) in premature infants strongly correlate with ROP development, indicating that IGF-I is one of these critical factors. Our preliminary work suggests that replacement of IGF-I to normal levels found in utero will prevent ROP and other complications of premature birth
The PREVENTROP consortium proposes during the project period to conduct preclinical studies in mice model of ROP and ra

Imagine that Insmed IS successful in their efforts to evaluate in 2016 new IPLEX initiatives, for instance ALS.

CONCLUSIONS
To date, IPLEX has been generally well tolera
ted and there have been no safety concerns
associated with IPLEX. Most of the patie
nts enrolled into the Program are at an
advanced stage of disease and a number of
patients have died while on IPLEX, but these
have been attributed by their physicians to dis
ease progression. It is
difficult to interpret
the changes of ALSFRS-R scores observe
d in the remaining
population because the
Program does not have a
concurrent control group.
www.fda.gov/downloads/Drugs/ResourcesForYou/HealthProfessionals/UCM173741.pdf

Yahoo! Finance Worldwide

Quotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.